Pertuzumab: beside an established treatment under test
85 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 1. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingNCT07772245Phase 2Report a problem
- De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early BreastNot yet recruitingNCT07748260Phase 3Report a problem
- Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNCT07687225Not applicableReport a problem
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3Report a problem
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingNCT07679269Phase 2Report a problem
- Elacestrant in Advanced Triple Positive Breast CancerRecruitingNCT07612215Phase 1/2Report a problem
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingNCT07578116Phase 3Report a problem
- Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled StudyNot yet recruitingNCT07533526Not applicableReport a problem
- HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term RemissionRecruitingNCT07459673Phase 2Report a problem
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementRecruitingNCT07371585Phase 2Report a problem
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelNot yet recruitingNCT07239271Phase 3Report a problem
- Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerRecruitingNCT07220135Phase 2Report a problem
- Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT07057427Phase 3Report a problem
- A Study of Surgery and Radiotherapy in People With Breast CancerRecruitingNCT07053085Phase 2Report a problem
- Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNCT06197581Not applicableReport a problem
- Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingNCT06135714Phase 3Report a problem
- The Choice of Treatment Methods and Efficacy of LABCRecruitingNCT06080620Not applicableReport a problem
- EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerRecruitingNCT05883852Phase 3Report a problem
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingNCT05760612Phase 3Report a problem
- To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyRecruitingNCT05656079Not applicableReport a problem
- A Study for the Adjuvant Treatment of Breast CancerRecruitingNCT05420467Phase 4Report a problem
- A Study for the Neoadjuvant Treatment of Breast CancerRecruitingNCT05420454Phase 4Report a problem
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingNCT05159193Phase 3Report a problem
- Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)RecruitingNCT04858529Phase 3Report a problem
- A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT04547907Phase 3Report a problem
- Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast CancerNot yet recruitingNCT04337658Phase 3Report a problem
- Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)Not yet recruitingNCT04301375Phase 2Report a problem
- Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)RecruitingNCT04293796Not applicableReport a problem
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Phase 3Results postedReport a problem
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive, not recruitingNCT05113251Phase 3Results postedReport a problem
- Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant TherapyTerminatedNCT04578106Phase 2Results postedReport a problem
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerTerminatedNCT04108858Phase 1/2Results postedReport a problem
- Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerActive, not recruitingNCT04001829Phase 2Results postedReport a problem
- Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results postedReport a problem
- Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Active, not recruitingNCT03747120Phase 2Results postedReport a problem
- Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)CompletedNCT03742986Phase 2Results postedReport a problem
- A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerCompletedNCT03726879Phase 3Results postedReport a problem
- To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)CompletedNCT03644186Phase 2Results postedReport a problem
- Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BCCompletedNCT03417544Phase 2Results postedReport a problem
- Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast CancerTerminatedNCT03329378Phase 2Results postedReport a problem
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerTerminatedNCT03199885Phase 3Results postedReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results postedReport a problem
- A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT02131064Phase 3Results postedReport a problem
- A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02019277Phase 3Results postedReport a problem
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerCompletedNCT02003209Phase 3Results postedReport a problem
- A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerCompletedNCT01966471Phase 3Results postedReport a problem
- Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant ChemotherapyCompletedNCT01847001Phase 2Results postedReport a problem
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast CancerActive, not recruitingNCT07421141Phase 2Report a problem
- A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast CancerStatus unknownNCT05871918Phase 3Report a problem
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2Report a problem
- Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2Report a problem
- Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)Status unknownNCT05036005Phase 4Report a problem
- Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast CancerStatus unknownNCT04665986Phase 3Report a problem
- A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingNCT04538742Phase 1/2Report a problem
- Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast CancerWithdrawnNCT04419181Phase 2Report a problem
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruitingNCT04266249Phase 2Report a problem
- Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationActive, not recruitingNCT04208178Phase 3Report a problem
- Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingNCT04193059Phase 3Report a problem
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCActive, not recruitingNCT04172259Phase 2Report a problem
- TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast CancerStatus unknownNCT04094896Phase 2Report a problem
- A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)CompletedNCT03988036Phase 2Report a problem
- Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerTerminatedNCT03894007Phase 2Report a problem
- TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After SurgeryStatus unknownNCT03881878Phase 1/2Report a problem
- Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 StudyActive, not recruitingNCT03820063Phase 2Report a problem
- A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast CancerWithdrawnNCT03811418Phase 3Report a problem
- Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerActive, not recruitingNCT03595592Phase 3Report a problem
- Omission of Radiation in Patients With Her-2 Positive Breast CancerActive, not recruitingNCT03460067Not applicableReport a problem
- Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic CancersWithdrawnNCT03323424Phase 2Report a problem
- Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsCompletedNCT03272477Phase 2Report a problem
- A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + TrastuzumabCompletedNCT03264547Phase 3Report a problem
- Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast CancerStatus unknownNCT03238495Phase 2Report a problem
- Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsStatus unknownNCT03144947Phase 2Report a problem
- Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabCompletedNCT03135171Phase 1Report a problem
- Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerActive, not recruitingNCT03125928Phase 2Report a problem
- Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast CancerWithdrawnNCT03058939Phase 2Report a problem
- Denosumab as an add-on Neoadjuvant Treatment (GeparX)CompletedNCT02682693Phase 2Report a problem
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "CompletedNCT02530424Phase 2Report a problem
- Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast CancerCompletedNCT02402712Phase 3Report a problem
- Detect V / CHEVENDO (Chemo vs. Endo)Active, not recruitingNCT02344472Phase 3Report a problem
- Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A StatusCompletedNCT02339532Phase 2Report a problem
- A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)CompletedNCT02125344Phase 3Report a problem
- Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2Active, not recruitingNCT01996267Phase 3Report a problem
- Trastuzumab & Pertuzumab Followed by T-DM1 in MBCCompletedNCT01835236Phase 2Report a problem
- Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1CompletedNCT01597414Phase 2Report a problem
- Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)CompletedNCT01583426Phase 3Report a problem